Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary

April 29, 2026

New York Stock Exchange US Information Technology Electronic Equipment, Instruments and Components earnings 58 min

Earnings Call Speaker Segments

Eric Linn

executive
#1

Thanks, Maria. Good morning, everyone, and welcome to the earnings conference call for Mirion's first quarter of 2026. With me this morning are Tom Logan, who is Mirion's Founder, Chairman, and CEO, and Brian Schopfer, who serves as Mirion's CFO and President of the Medical Group. Before we get into today's prepared remarks, I want to remind everyone that during this call we will be making forward-looking statements, and it's possible that actual results could differ materially from what those forward-looking statements project. The factors that might cause actual results to differ are laid out in our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and in Mirion's other SEC filings, under the caption Risk Factors. Any quarterly references in today's discussion relate to the first quarter, which ended March 31st, 2026, unless we note otherwise. Today's comments will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. You can find a reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix of the presentation that accompanies today's call. All of our earnings materials are available in the investor relations section of our website, www.mirion.com; and with that, I'll hand the call over to Tom, who will start on panel three.

Tom Logan

executive
#2

Eric, I really appreciate it. And I want to thank all of you for being on this call about our first quarter results. We've gotten off to a robust beginning in 2026, with order generation in the first quarter that was substantial. For our business, orders serve as a bellwether. They rose 19% during the first quarter, reaching $241 million, when you leave out growth tied to M&A. When M&A growth from Paragon and Certrec is counted, orders climbed 42%, hitting $288 million. The mix of order volume stood out as notably diverse. Meaningful gains occurred in both segments, among them our RTQA medical business, which had encountered headwinds during 2025. Noticeable backlog expansion is now resulting from this. Backlog stands at $1.1 billion in total, which is 19% higher excluding M&A, or 38% higher counting M&A. Within the nuclear and safety segment, our nuclear power end market keeps setting the pace. Growth in nuclear power orders and revenue came mainly from reactors operating today as well as small modular reactors, or SMRs. Another $43 million in orders came from Paragon during the quarter. The value the Paragon team creates continues to impress us. Because of what their solutions look like, when it comes to momentum from the nuclear power installed base, they really are the tip of the spear. The existing nuclear fleet is nearing middle age, so reinvestment matters greatly if capacity is to be maintained and raised via power uprates. Later this morning we'll take time to detail our progress on the large opportunity order pipeline, though let me offer a hint of that discussion by pointing out that $50 million of those large opportunity orders were secured by us in Q1. On top of that, in April we captured an extra $35 million in orders tied to SMRs. The remainder of the pipeline is still intact. Our conviction remains high regarding our right to win. The growing demand for nuclear power that we observe mirrors market tailwinds that keep strengthening. This momentum keeps compounding. Recent geopolitical developments underscore how necessary onshore, secure baseload energy is. Ten years ago, operators zeroed in on speeding up plant shutdowns, and severe capital rationing weighed on OpEx and CapEx budgets. Nowadays, their focus is on operating cycles of 100 years plus plant modernization, and both of those have a deep effect on capital spending plans. We notice this most directly in Paragon and Certrec, with a sizable follow-on opportunity for Mirion instrumentation and controls along with digitally enabled radiation protection solutions. Keep in mind that this dynamic is strong and does not depend on future assumptions regarding demand growth driven by AI. Available compute is what limits AI growth, and energy availability is what constrains that compute most profoundly. Also keep in mind that more than 80% of our nuclear power revenue comes from the installed base. New nuclear projects are upside, carrying strong optionality linked to development plans at both the SMR and utility scale. Panel four puts numbers to the effect of just a handful of recent prominent nuclear power headlines, which underscore the surge in worldwide demand for nuclear power. Within the U.S., the Department of Energy's UPRISE initiative is intended to raise existing nuclear power capacity by 2.5 GW by 2027 and 5 GW by 2029. The strain on power demand is severe enough that the DOE alongside utilities are moving quickly to speed up capital deployment, aiming to get more nuclear output from plants that already exist. That fits within a wider effort by the Trump administration to grow U.S. nuclear energy capacity, taking it from roughly 100 GW at present up to 400 GW come 2050. On top of that, the energy shock caused by recent geopolitical uncertainty has made plain the dangers of depending on imported fossil fuels across many regions. That is intensifying attention on energy security, onshoring, and decarbonization. Across all three of those priorities, nuclear power is being seen more and more as a central answer, particularly for nations whose energy needs are under growing strain from a shifting world order; taken together, just these two headlines will contribute an estimated 8 GW to 15 GW of nuclear power generation. Out of that additional capacity, roughly 3 GW to 5 GW is incremental to the U.S. market, which underscores how important our U.S.-based Paragon and Certrec acquisitions are. Another point worth making: U.S. utilities have pledged $1.4 trillion in planned capital expenditures through 2030, which is a 21% increase over projections from only one year ago. Firms such as Duke Energy are projecting over $100 billion in their planned five-year capital spend. NextEra sits not far behind at approximately $94 billion. Every one of these is a current Mirion customer. Panel five covers Paragon's integration progress along with first quarter financial contributions. Through both the Paragon and Certrec acquisitions, Mirion is being positioned to serve the U.S. market at precisely the right moment. We completed these acquisitions before the full scope of the existing fleet capital cycle had become broadly visible to the market. Commercial synergy opportunities are becoming clearer as utilities and the federal government pour capital into the operating reactor fleet. As a reminder, we have content in every single reactor within North America and approximately 98% of the global operating fleet. The synergy opportunities are significant. For instance, Paragon's products and engineering capabilities will let Mirion widen our scope so we can compete better for power uprate and digital modernization projects. Certrec's regulatory and workforce software is a compelling solution for today's labor-constrained environment; this addition gives Mirion a software and services revenue layer that compounds within our hardware footprint at every plant. With these combined offerings, Mirion can now provide customers more integrated solutions spanning laboratory instruments, safety and security systems, qualified equipment, radiation protection, and regulatory and workforce software. No competitor in the U.S. nuclear market has that breadth. These acquisitions will deliver revenue synergies, customer access synergies, and platform synergies at exactly the moment the market is asking for all three; we're already seeing this materializing in Paragon's financial performance. Paragon's first quarter revenue grew 45%, reflecting a broad-based increase in demand. This accelerating revenue is improving their operating leverage and helping to expand margins. We spoke with you last quarter about the planned cadence of integration efforts; we're pleased to report that we have identified additional synergy opportunities. Teams from the legacy businesses are working hand in hand, and customers can't wait to capture what a merged Mirion, Paragon, and Certrec can deliver. Putting the customer experience first, we're running joint engagements with customers across strategic accounts. Incremental order wins are already coming out of these efforts. To illustrate, by leaning on relationships Paragon already had with important strategic customers, we landed a sizable order for products from legacy Mirion; that's an early sign of what will turn into standard practice once our companies are combined. Every one of these data points is producing concrete gains for Mirion, and panel six makes that clearest in our backlog. With Q4 and Q1 both posting strong orders one after the other, our backlog has shifted by a step change. Following 2 years in which backlog grew only nominally, the nuclear dynamic we've talked about is now becoming real opportunity for our company. We've told investors repeatedly that turning orders into revenue can require multiple quarters or even years. Obviously, the backlog is growing in a meaningful way, and that comes before revenue growth accelerates down the road. Before handing things to Brian, panel seven lays out the progress that keeps happening in the medical segment. Our RTQA end market, roughly half of the segment's revenue, saw encouraging activity. Keep in mind that during 2025 we faced multiple headwinds, at home and overseas. On a positive note, hardware activity is starting to strengthen while software activity stays a standout; within the U.S., we booked a large radiation-tolerant camera order connected to the Varian partnership. That relationship matters greatly, given that Varian is the industry's top OEM. We're eager to back this relationship and other key accounts with the sort of new product innovation that made this important order possible; in nuclear medicine, we're still on track for double-digit organic revenue growth in 2026. That would mark our second straight year of double-digit organic growth in nuclear medicine. Because we lead the market with key hardware offerings such as Dose Calibrators and Thyroid Uptake Systems, we're an essential supplier to the expanding radiopharma ecosystem; on top of that, we're extending our international footprint to seize infrastructure growth in other countries; we think our ec² software platform will open expanding opportunities throughout the radiopharmaceutical landscape, from drug discovery all the way to clinical administration. As more targeted radiopharmaceutical therapies reach the market, this opportunity will grow substantially. Finally, Dosimetry Services stays a compelling business. This end market is a dependable franchise expanding at GDP plus throughout the cycle. At the same time, it reliably delivers strong margins and remains an appealing recurring revenue platform. Our wider shift from analog offerings to digital ones will keep going, unlocking extra margin upside as time passes. As an aside, we take pride in the fact that those aboard the recent Artemis Lunar Mission wore a customized version of our digital dosimeters to keep watch over their radiation safety. Even more significantly, interest in our digital dosimetry offerings has been sparked among many key nuclear power accounts, which opens cross-sell opportunities to grow past a business that has historically centered on medical uses. At this point, I'll hand things over to Brian so he can take us through the financials. Brian?

Brian Schopfer

executive
#3

Thanks, Tom, and good morning, everyone, joining us today. I'll pick up the prepared remarks at slide eight, where we lay out how we performed financially. Total revenue for the first quarter came in at $258 million, which is 28% higher than the first quarter of last year. Organic growth in revenue reached 3%, matching what we expected and consistent with the message we gave in February. Adjusted EBITDA for the first quarter stood at $54 million, which is 16% above the prior year. As we flagged back in February, margins narrowed during the quarter, a result of M&A margin dilution, one-timers from Q1 of last year, and a mix shift within the legacy nuclear and safety segment, largely tied to our sensing business. We used roughly $16 million out of our $100 million share repurchase program during the first quarter, buying back about 700,000 shares. That mirrors what we did in last year's first quarter to offset dilution from our annual stock-based compensation program; adjusted free cash flow generated in the quarter was $11 million. Historically, Q1 is our weakest quarter for cash flow generation. Cash generation tied to our project business can be uneven, and that's exactly what happened in Q1, with fewer project inflows than we had a year ago. Looking at the quarters ahead, we can see a far stronger cash generation profile and improved working capital dynamics. Finally, as Tom described, first quarter orders were robust, with both segments contributing growth. Slide nine lays out the details. Order performance stood out as the quarter's highlight. Setting aside any order growth tied to M&A, core orders rose almost 20%, with growth in both segments. Total orders, which include a $47 million contribution from Paragon and Certrec, were up 42% for the quarter, reaching $288 million. Within nuclear and safety, orders increased across all three end markets: nuclear power, labs and research, and defense and diversifieds. In nuclear power, the growth mainly reflects two sizable installed base orders within the U.S. operating fleet plus a large SMR order. At Paragon, we booked an incremental large order within the U.S. installed base. The SMR related order worth approximately $35 million that we were awarded in April will appear in the Q2 orders figure. Labs and research orders grew mainly out of Europe even though we were comping against a $5 million DOE order from last year. One thing worth noting at Paragon is that we saw strong DOE related order activity during the quarter. Our DOE pipeline across the company is very strong. Finally, defense and diversified orders grew in the quarter, helped by a radioactive waste handling order, which formed part of our large opportunity pipeline. In the medical segment, order growth mainly reflects the radiation hardened cameras order within the RTQA end market; that gives us solid backlog in that new product for the next three years. Slide 10 offers the latest update on our large opportunity pipeline. Two of the five large opportunity orders are Paragon related. During Q1, we secured the initial portion of an SMR order, a piece of a radioactive waste handling contract in our defense and diversified end market, a Paragon large battery qualification order from within the installed base, and a sizable medical order for radiation hardened cameras coming from our RTQA business. What's interesting and significant is that neither the RTQA nor the battery orders appeared in our pipeline when the year closed, which shows just how much the environment keeps shifting. On a separate note, in April we received the first portion of yet another large Paragon SMR order. The remaining pipeline is still active and keeps presenting a meaningful opportunity for the company, including the leftover pieces of those three partial orders I just referenced. Before I go into the quarter's financial results, let me take a moment to walk through the nuclear power end market on slide 11. Nuclear power orders, not counting M&A, rose 15% during the first quarter, which includes the large partial SMR order. SMR orders keep delivering impressive results. We booked roughly $15 million of orders during the quarter, and then came the $35 million large opportunity awarded to us in April. Momentum keeps building in this segment of nuclear power. Let's move into the quarterly financials starting on slide 12. Consolidated first quarter revenue rose 27.5% to $258 million. Roughly 21 of that 27.5% growth came from acquisitions, mainly Paragon. Organic revenue growth of 3% matched our expectations. As a reminder, on our February earnings call, we said we anticipated organic revenue growth in the low single digits for the first quarter. First quarter adjusted EBITDA reached $54 million, or 16% above last year's first quarter. As we signaled on our February earnings call, adjusted EBITDA margins narrowed. The main reasons were the margin dilutive impact from M&A, plus some mix impacts combined with one-timers in the legacy business; we anticipate margin expansion across the next three quarters within the legacy business, offset by Paragon. Adjusted EPS came to $0.10 per share for the quarter. In 2026, we are now factoring stock-based comp into our adjusted EPS calculation. Using a methodology similar to the one established for 2026, last year's adjusted EPS would have been $0.08 per share. There's an adjusted EPS reconciliation slide in the appendix containing the details for your modeling. Moving to the nuclear and safety segment on slide 13, first quarter revenue was $186 million, up 39%. Organic revenue came in 2.6% above our expectations of flat year-over-year that we noted in February. A few items stand out as particularly interesting in the first quarter. First, nuclear power related revenue, excluding M&A, climbed 4% compared to last year. I'd point out that for the first quarter, we were comping 18%. We saw growth across both our installed base markets of North America and Europe. That was offset by reduced new build revenue in Asia, primarily China and Korea. We still anticipate double-digit revenue growth in the nuclear power end market for the full year. Second, revenue tied to SMRs is picking up speed. That represents 2% of Mirion's overall revenue, and by the time the year ends, it should climb past 3% of the total. Third, organic growth in the labs and research end market came in above what we had anticipated, driven by a robust showing in North America. Fourth, within our defense end market, we recorded greater revenue from NATO as well as U.S. military and civil defense programs. Keep in mind that the defense end market tends to be uneven, though momentum has clearly strengthened. Adjusted EBITDA rose by almost $8 million, or 19%, reaching $47 million. As already covered, margins for nuclear and safety adjusted EBITDA narrowed. M&A accounted for half of that narrowing. The remaining half largely reflected shifts in mix, including the sensing business, the count of one-time items in the comparable prior-year period, and broader mix dynamics inside our North America business. Finally, note that we were up against more than 300 basis points of margin expansion in Q1 2025, which was the biggest of any quarter in 2025 for this segment. Turning now to the Medical segment on slide 14. First quarter revenue came to $72 million, a rise of 5%.

Brian Schopfer

executive
#4

Organic revenue growth came in at about 4%, matching the mid-single-digit organic revenue growth we had signaled on the February earnings call. Within our RTQA end market, organic revenue growth reached double digits, helped by an easier comparison against last year's ERP implementation headwinds, solid software results, and roughly a month of output from the sizable camera order we booked. For nuclear medicine, we anticipate that most of the organic revenue growth will land in the second half of the year. At the same time, organic growth in our Dosimetry Services end market declined slightly. That business faced a tough comparison because of a big hardware order from last year, something we've covered previously. Setting that aside, core Dosimetry Services organic revenue would have increased at a low single-digit rate during Q1. Adjusted EBITDA for the Medical segment in Q1 reached $25 million, which is 6% above last year. Margins widened during the quarter as anticipated, driven by operating leverage along with favorable pricing. Now to adjusted free cash flow, shown on slide 15: we produced $11 million of it during the first quarter. The gap relative to last year stems mainly from timing effects on networking capital. Even though networking capital absorbed a significant amount of cash this quarter, the structural improvements we've made to our balance sheet paid off during the period through the interest expense line. We're still on track to hit our full-year adjusted free cash flow guidance, and we view Q1 as the low point. We keep seeing substantial room to improve in AR, inventory, and our project cash flows. More broadly, regarding the 2026 guidance on slide 16, nothing has changed from what we disclosed on the February earnings call, aside from a minor tweak to adjusted EPS to reflect the one-time CEO retention grant of performance vesting stock options that we disclosed earlier this month. Before we take your questions, let me share a few points on second quarter expectations. Starting with orders: second quarter orders should come in above the first quarter. We anticipate yet another quarter of robust order growth, with sequential growth from Q1 to Q2 expected at 15%-20%. Consolidated organic revenue growth for the second quarter should be in the low single digits, and each operating segment should see the same. Keep in mind that on both the top and bottom line, we shipped a considerable amount of product into China during the second quarter of 2025 ahead of tariffs taking effect. That creates a headwind for this quarter. Consolidated adjusted EBITDA margins ought to be roughly flat compared with Q2 2025. Adjusted EBITDA margins for the Nuclear and Safety segment should likewise be roughly flat, even with the margin dilutive effects of the Paragon acquisition. If you set aside Paragon's margin dilutive impact, adjusted EBITDA margins for the Nuclear and Safety segment should expand. On Paragon, our projection is for revenue in the second quarter to come in a touch below the first quarter, though it will still deliver double-digit growth compared with a year ago. For the full year, we're holding to what we said before — roughly 25% revenue growth for Paragon — and we still look for EBITDA margins in the low 20s. And finally, margins in the Medical segment ought to improve a bit. Keep in mind that in last year's second quarter, Medical segment margins rose by nearly 300 basis points, so we're up against another difficult comparison in that segment. With that said, we're ready to take your questions. Operator?

James West

analyst
#5

Thanks. Good morning, guys.

Brian Schopfer

executive
#6

Morning, James.

James West

analyst
#7

Tom, during your prepared remarks you made a few macro points. Given that I saw you back in February and you already seemed quite optimistic at that time, plus the Middle East conflict happened after, I'd really like to hear you expand on that a bit. As you know well, the DOE has been quite active in guiding nuclear forward. I'm curious whether there's been — and I'm confident there has — what are you observing when it comes to the pace of the nuclear build-out picking up in the U.S., and also the nuclear renaissance we're witnessing on a broader global scale?

Tom Logan

executive
#8

Yeah, James. Overall, I'd say there are 3 key dimensions here. By far the most significant one is the dynamic that the installed base is going through right now. Keep in mind that currently, if you look at the American nuclear fleet, it's operating at very high capacity factors — generally somewhere in the low 90% range. On a global basis, we just got updated statistics showing that the global fleet ran at roughly an 82% capacity factor last year. The key takeaway is that a handful of significant developments have fundamentally shifted the psychology of the people who own those assets. First, as I mentioned in my commentary, just a few years back the stance was highly defensive. A lot of nuclear power plants were running on very thin margins, or even margins that were negative. The prevailing mindset leaned toward premature decommissioning of nuclear power plants, along with an extremely defensive CapEx and OpEx posture designed to keep the associated expense as low as possible. Today we're seeing the complete reverse. Because even with AI demand at its current level, the world simply lacks sufficient electrical generating capacity, and in any reasonable scenario that will always be the limiting factor. That has produced a very compelling economic incentive for operators to fundamentally alter how they manage these assets. The biggest single effect is that although life extensions are happening in the American market — going from 60 years of permitted operating life up to 80 years — most operators are actually thinking about 100. If you picture that psychological shift, moving from a shutdown mindset to one where I want to keep running these assets for another 40 years, it has a profound impact on the solutions they require to shore up these power plants. Most immediately, we see that reflected in Certrec and Paragon through their various activities, which are essential to the daily operation of the power plant. Just beyond that, what we're seeing is both a compelling need and a compelling opportunity to broadly upgrade Instrumentation and Control systems, which encompass in-core detection, neutron flux measurement, radiation monitoring systems, and reactor protection systems. On top of that, there's a need to upgrade, consolidate, and digitally enable radiation protection systems; we're starting to see the leading edge of that demand right now, and not only in the U.S. On a worldwide level, not simply this one market—honestly, I can't emphasize enough how deeply this changes the total set of opportunities tied to the worldwide operating fleet. It's obvious that activity is picking up considerably around advanced reactors, what people call small modular reactors. That shows up in our backlog, naturally; consider the top players—if you took the 20 SMR companies with the strongest balance sheets and the greatest technological maturity, we essentially dominate that group when it comes to standing, orders on the books, and depth of involvement. Our outlook on that segment is extremely positive; it keeps shifting earlier, and most recently it gained support from X-Energy's IPO, which has performed very, very strongly during the past week. On top of that, there's utility scale. The activity we've mentioned before with Westinghouse, which intends to construct 14 AP1000s abroad—nine in Ukraine, three in Poland, two in Bulgaria—plus an early commitment from the Indians for another six, and potentially 10 more AP1000s in the American market, will clearly factor into all of it. Then there's EDF Framatome, which in the near term plans to start three projects in France: at Penly, Bugey, and Gravelines. Because of our strategic alliance with EDF Framatome, we anticipate participating there as well. After that comes Rosatom, then KHNP, KEPCO, the Koreans, and ongoing work in China. What we observe across the board is also a speeding up of commitments for new builds, and that clearly strengthens the entire nuclear case for us.

James West

analyst
#9

That's quite useful, Tom. I appreciate it. Perhaps for Brian — the medical segment performed rather well during this quarter. I realize 2025 proved to be a tougher year, with numerous headwinds. Does this represent a singular event, or have those headwinds finally cleared, meaning we ought to anticipate similar results from medical moving forward?

Brian Schopfer

executive
#10

Yeah. Well, listen, we are, as you know, holding firm on our full-year guidance for medical. From where things stood when the year began compared with now, I'd say we're — no figures have been revised at all, yet I believe we remain increasingly hopeful in how we see things, that this operation has green shoots, so to speak, emerging. We're continuing to keep an eye on Asian markets, since that's where a lot of our difficulties have arisen, along with the U.S. market. Our software operation keeps delivering solid results. Our services operation keeps shaping up well, or delivering well. That order we secured with Varian genuinely helps shore up some backlog for this year plus the coming 2 years, and it represents solid business for us. I'd put it this way — our guidance range hasn't been altered, though I'd say our degree of confidence has improved compared with where it stood merely 3 months back.

Joe Ritchie

analyst
#11

Hey, guys. Good morning.

Brian Schopfer

executive
#12

Hey, Joe.

Tom Logan

executive
#13

Good morning.

Joe Ritchie

analyst
#14

I was thinking... Well, what you said about the order backlog was quite encouraging, and not only for this quarter but also for how the second quarter has begun. Could you perhaps share a bit more detail? Clearly, the $35 million SMR order is included in 2Q. Maybe just some additional information about that 15%-20% sequential increase you're anticipating for orders.

Brian Schopfer

executive
#15

Yes.

Joe Ritchie

analyst
#16

It would be useful to get that for Q2. Thanks.

Brian Schopfer

executive
#17

I believe it reflects all the points Tom just raised — namely that, as you know, things keep going well for us in the nuclear sector. Clearly, we anticipate, you know, one more order, or a handful, on the bigger end. As for when those land, that's always somewhat, you know, tough to call. For us to reach those figures, that has to be included. Once again, you know, the way orders are behaving keeps working in our favor. I'd rather not discuss any particular project, since, you know, these situations shift somewhat. I do find it quite encouraging that the team, the teams feel we'll get something like quarter-over-quarter order growth compared with a year earlier. If you recall last year, we were somewhat level, you know, in orders from Q1 to Q2 too. Clearly this represents a step change. Paragon plays a part in that too. I think, you know, the flywheel is starting to turn. I think we're still in the early stages. Perhaps one more remark, Joe.

Joe Ritchie

analyst
#18

Sure.

Brian Schopfer

executive
#19

Another good sign is that a year ago, the big orders all landed in Q4. What I think folks ought to pay attention to is that this year, we're seeing that happen a lot sooner. First, that definitely creates revenue potential for us this year. But honestly, when you look at materiality, a lot of these bigger orders will likely fall into 2027 rather than 2026. Second, there's no sitting around waiting to find out if this is real. This is going to keep happening quarter after quarter. You'll watch certain items get checked off from that pipeline. To me, that's really encouraging. It's a good sign, and it demonstrates that the momentum is favorable. Let me just repeat one point. Two orders worth more than $10 million that we booked in Q1 weren't anywhere in our pipeline when the year ended. That, I think, says something very encouraging about what else we're seeing.

Tom Logan

executive
#20

Joe, one more item I want to mention is that Doug VanTassell, who serves as Paragon's CEO, and I have been on a structured roadshow alongside chief nuclear officers from across the American fleet. Honestly, what's being said in those conversations is remarkable. Once again, there's no way to exaggerate how much the combined Mirion and Paragon sales force matters. You see, the teams from Mirion and Paragon — those folks operate like apex predators. Their devotion to keeping customers satisfied borders on maniacal. What we're finding is that this additional dialogue, this deeper closeness with customers, is genuinely widening the aperture when we consider what opportunities exist, whether we look at the short term or further out.

Joe Ritchie

analyst
#21

Yeah, that's really useful, and clearly Paragon is off to a strong beginning for you folks. So maybe this is just my follow-up, and it actually flows nicely from what you mentioned before, Brian, about that backlog conversion. There are really 2 questions here, correct? When you look at the guidance and the way you'd established it for 2026, perhaps just discuss a bit how much confidence you have about achieving that EBITDA ramp as the year goes on. And then second, since the backlog is now changing in a major way, how much visibility are you beginning to have into 2027, given that a few of these items might be somewhat longer cycle?

Brian Schopfer

executive
#22

Yeah. I'd say a couple of things. If our view on EBITDA revenue guidance were different, we would have adjusted during the quarter. That's what we've, you know, always done — when we see it, we call it. I believe we remain confident in our guide. And as you consider, you know, 2027, you know, I'd say 2026 is truly somewhat back-end loaded. That's obvious since you've seen the first quarter, and I provided guidance on the second quarter. I also believe that affects how we're beginning to see and consider 2027 taking shape. Obviously I won't guide that at this point, but I think we're quite constructive about what we're seeing, you know, past 2026, and I think that's reflected in the backlog.

Tom Logan

executive
#23

If you simply run the numbers, you're going to notice, by the way, that backlog will increase once more during Q2. In my view, that puts us in a solid position.

Andy Kaplowitz

analyst
#24

Hey, good morning, everyone.

Tom Logan

executive
#25

Andy.

Andy Kaplowitz

analyst
#26

Perhaps a slight follow-up regarding that point. Nothing was altered when it comes to your visibility on the segment revenue growth you expect for this year; within nuclear and safety, you began flat, which was anticipated for nuclear power. Could you perhaps discuss the visibility toward returning to double digits, as you mentioned you would? Do you essentially possess the order coverage that gives you Q1, along with your remarks about Q2, or is it still necessary to witness some larger nuclear power orders in order to achieve that double-digit growth in 2026?

Brian Schopfer

executive
#27

Yes. I mean, listen, I believe the comparison set becomes somewhat simpler as the quarters progress on the nuclear power side, quarter by quarter. As you know, Q1 represented our biggest nuclear power sort of comparison for 2025. That is one, I think. I think if you examine the order, you know, including simply the large order dynamics and what we are observing, I mean, it is certainly heavily weighted toward nuclear power; we remain fond of double-digit growth in 2026 for nuclear power. Incidentally, that is-

Andy Kaplowitz

analyst
#28

Okay. Got it.

Brian Schopfer

executive
#29

That's pre-Paragon double-digit growth.

Andy Kaplowitz

analyst
#30

Right.

Brian Schopfer

executive
#31

So, when it comes to Paragon, a big chunk of their sales comes from nuclear power, as we've been discussing. Even though we've already mentioned the DOE situation, we are definitely beginning to see signs of progress. Their order growth was really strong. To put it in context for Paragon, that's roughly 25% organic growth, assuming we own them during 2025 and 2026. So I'd say we're encouraged by what's taking shape in the nuclear power segment for both brands.

Andy Kaplowitz

analyst
#32

That's really useful. Moving to medical, where things look somewhat comparable — your outlook for RTQA in 2026 stayed the same, yet you brought up green shoots during Q1 along with hardware, and clearly that big camera order tied to Varian comes across as pretty compelling. As I recall, you shared news of a tighter partnership with Varian, possibly around 1.5 years back or so. Could you shed a bit more light on whether RTQA ought to be finding additional openings with Varian now, and whether growth should be picking up speed going forward?

Brian Schopfer

executive
#33

Perhaps I'll handle that one and you can jump in. I mean, look, we're only one quarter in. You know, I think we'd like to observe how things unfold over the rest of the year. Once more, that RTQA order wasn't something we were tracking six months ago. So I think that hands us a bit of extra visibility. Let's make it past the second quarter, which stands as our hardest comparison by a wide margin within the RTQA business, thanks to the China shipments, and so on. As I mentioned, I believe in a remark I made earlier, I think our conviction regarding the medical figure is stronger today than it was, you know, back in February.

Tomo Sano

analyst
#34

Hi, good morning, Tom and Brian.

Tom Logan

executive
#35

Morning.

Brian Schopfer

executive
#36

Good morning.

Tomo Sano

analyst
#37

Thanks. I'd like to ask about Paragon, which has posted impressive contract signings and is expanding. Could you bring us up to date on how the integration is going, how well the cultures are meshing, and in particular what R&D cost synergies have been achieved up to now? And does the goal of an adjusted EBITDA margin above 30% for 2028 still hold following the acquisitions? Any details would be welcome. Thanks.

Tom Logan

executive
#38

Yeah, Tomo, let me kick things off. First, regarding how the cultures mesh, I believe that was truly a decisive factor in why we were able to buy Paragon in the first place, since the two organizations share such a strong degree of cultural compatibility; both are highly entrepreneurial, very risk-on, very engaged, and very driven to build a terrific business. The cultural symbiosis uniting Paragon and Mirion is exceptionally strong. To a very pleasing degree, we're seeing that reflected in these early stages of integration, as the two organizations have largely come together in a highly collaborative way. Looking ahead, with both parties working as partners, everyone involved is getting more and more excited about what's achievable here—what we can get done together and how strongly it all aligns; on the synergy side, our usual approach follows a first principle of the Hippocratic Oath, which means the top priority is never causing damage. Each time we acquire a new asset, we're careful to move forward side by side, to gain knowledge from each other, and to stay highly deliberate when identifying where the opportunities lie. Once that's done, infrastructure becomes our foremost focus. So what that involves is essentially wiring together the whole organization — getting everyone on the same health and welfare benefits, the same HR procedures, the same IT, the same financial and accounting rules and workflows, that kind of thing. Once that's done, we shift our attention to the commercial side of the synergies, since we've always viewed that as the largest single piece of the investment thesis behind this deal. We've mentioned this before, and I think it's obvious by now, but the returns there are coming in faster than we'd anticipated; there's a substantial chance to build up and expand the commercial pull available to us on both sides, and you can already see evidence of that in the backlog. Beyond that, there's cost optimization, and beyond that, there's technological leverage, since we're bringing the enhanced capabilities of every organization into our R&D pipeline and truly changing the way we approach new product solutions along with the improved technological components that will support them. Over the short term, no, we aren't pinpointing any specific cost synergies. I would say our history on this front is outstanding. Maybe the strongest recent example, simply because of how large it was, is the Sun Nuclear acquisition, which closed in 2020. In that case, we acquired a terrific company, a highly dynamic one performing well, and since becoming its owner, we've increased that business's margin by about 10 points. We definitely expect Paragon to add to our earnings. Of course, we're eager and motivated to see that happen as soon as possible. Just so we're clear, this is something we all share. It's not a case of Mirion pushing for it while Paragon drags its feet. I believe everyone is committed to moving this forward, and we aim to get there very fast. Last thing: regarding that 30% EBITDA goal for 2028 that we laid out at our investor day a couple years back, we're still holding to it. This year, I believe our guidance was 25%-26% EBITDA margins. Naturally, we're working to reach the top of that range. Assuming that, you'd be looking at a further four points of margin improvement across the coming two years. We anticipate that at least half of it will result from absorption, since we keep pushing higher volumes through a cost base that's mostly fixed and rises far more slowly than what we can achieve on pricing at the top line. As for the other two points, that last chunk of upside is going to come from self-help. Specifically, that means further gains in how we buy and how we convert, more streamlining of our manufacturing network as a whole, and sharper approaches to pricing. And the biggest lever of all, obviously, is AI. Right now we're putting a lot of money into AI, and you could say that over the short term — our guidance shows this — it works against our margins. Everything else comes down to a decision we make. Whenever I choose to, I'm able to strike that balance with the go-get. That's something we control completely as an organization. And once more, because of the stronger capabilities we're seeing — whether for cutting costs and boosting efficiency on our own side, or for advancing the products our customers use — we feel quite optimistic about our capacity to reach that goal.

Tomo Sano

analyst
#39

Thanks, Tom. I just have one more question about your nuclear medicine segment. Would you be able to talk through where sales stand right now and what you expect ahead, plus how margins look and what will mainly drive expansion and earnings down the road?

Brian Schopfer

executive
#40

That's quite a follow-up there, Tomo. What I mentioned during my prepared comments is that we expected the organic growth for that unit to lean somewhat more toward the back half. This one resembles Sun, honestly. It's a terrific margin narrative. Between 2020 and 2023 we acquired those 3 companies and merged them; I believe ec² was one of them. Even as a group, it was an EBITDA business in the single digits, and now it boosts Mirion's overall margin profile. We still appreciate our capacity to widen those margins as time passes. New products are one thing we're developing. That's likely a 2027 launch rather than a 2026 one. On the operations side, we're highly concentrated on sourcing, and on further trimming the workforce there. Growing is our top priority. We remain fond of that business. This year it does skew a bit to the back half. Still, we stay confident about our capacity to expand that business at a double-digit rate.

Quinn Fredrickson

analyst
#41

Yes, thank you. I'd like to inquire about the green shoots mentioned in the RTQA commentary. Brian, when you answered a previous question, you began discussing the Asian markets. How are things developing in those regions, particularly compared with what you anticipated, and are the advantages of certain measures you've implemented there beginning to show yet?

Brian Schopfer

executive
#42

Once again, I suppose I'd describe those as green shoots, correct? Some positive momentum is visible to us. The work Mark and the team have done to get us off on the right foot is something I'm pleased with. Seeing this reach fruition is going to require several quarters. Movement in those markets isn't always that quick. Our outlook on China is likely somewhat more positive. Regarding Japan, we remain a bit uncertain about the conditions there. We do have a solid strategy in place, and we're definitely pressing ahead. The deal involving Varian, I'd say, provides us with some welcome foundational steadiness in that RTQA — honestly, that particular product line was not, well, it's a newer one. All of that represents additional growth for us compared to last year. We're keeping an eye on the U.S. market as well. What we observed during the first quarter left us encouraged, I'd say. Once again, software services drove the results, though our hardware segment outperformed our projections for the first quarter. Look, we're not at the point where we'd revise those figures. My sense is that we'd like to see that business deliver somewhat more output first.

Quinn Fredrickson

analyst
#43

Thanks. I'm curious whether you can provide additional detail regarding that April SMR order worth $35 million. For an SMR, that appears to be a rather substantial order, and you mentioned additional business is still pending. Does that span several SMRs, or does it reflect a greater revenue opportunity per megawatt with Paragon? Any further context you're able to offer would be helpful.

Tom Logan

executive
#44

Sure, Quinn, this involves one leading SMR player; once again it supports what you could call the power plant's central nervous system, handling instrumentation and control. It's a solid win, you know. We at Paragon have spent considerable time working on this. Again, considering the overall activity level in this market, what we observe is a broad shift to the left in the dynamics, especially regarding these first-of-a-kind orders. Our stance on the SMR market as a whole keeps getting more constructive. As you know, we noted before that because of intrinsic scale diseconomies in Instrumentation and Control specifically, broadly speaking an SMR's revenue opportunity per megawatt of output runs considerably above what utility scale would offer. On earlier calls we gave a rough, loose estimate of roughly 60% higher, and that view is one we still hold.

Brian Schopfer

executive
#45

Right. I'd simply note that the 60% figure came before Paragon. We haven't calculated anything, nor have we provided guidance regarding what Paragon would look like. You're able to get a sense of the magnitude here.

Jeff Grampp

analyst
#46

Morning, guys.

Tom Logan

executive
#47

Morning.

Jeff Grampp

analyst
#48

I'd like to return to Paragon and was hoping you could go into a little more detail about that "tip-of-the-spear" type of description you use for them. What I'm wondering is whether that way of positioning them provides you with a distinct perspective on, or insight into, the potential growth that sits beneath nuclear power — one that maybe other products under what people refer to as legacy Mirion perhaps didn't give the company access to before Paragon came along? And really, any additional thoughts on what that sort of tip-of-the-spear role opens up for Mirion as a whole? Thanks.

Tom Logan

executive
#49

Yeah. Yeah, I'll handle that one. When you take a look at the legacy Paragon operation, essentially their business has centered on keeping power plants up and running. They supply essential spare parts, which in a lot of instances are no longer provided by the original OEM. Sometimes that involves reverse engineering electromechanical components that were previously offered in a power plant. Sometimes it involves taking a part you can buy commercially that lacks a nuclear qualification; that might be a backup generator, a chiller, batteries, or other components. Paragon runs that through a highly formal commercial-grade dedication process, turning it into a nuclear qualified component. On top of that, they also provide what amounts to a brokerage platform for spare parts that are available across the industry. Those three main activities, again, essentially keep the fleet running. They're an extremely important supplier to the industry as a whole. Because of how this business works, it seems intuitive that the degree of closeness with customers and the level of dialogue must be extremely high; that last element is really the key catalyst behind the stronger demand momentum we're seeing across Mirion products generally. On the other hand, looking at legacy Mirion products, our focus has been instrumentation and control via in-core and ex-core detectors, via neutron flux monitoring systems, via radiation monitoring systems, and also radio protection across many form factors, software, systems and services generally. That platform, or that historical portfolio, has likewise been enhanced by the complementary I&C capabilities Paragon brings. Once you combine all of this, first of all, because of the greater closeness of the Paragon sales team, we're seeing a demand signal from the power plants that is clearer and higher resolution than what we've historically seen, which was based on a fundamentally different sales approach at legacy Mirion; that is definitely raising our view and raising how bullish we are about what's taking place in the industry. On top of that, it also gives us far earlier conversation about those complementary areas of overlap on that Venn diagram, especially in Instrumentation and Control. We're thrilled by this acquisition. We're thrilled to bring our two companies together. This is a great pickup for us.

Nick Amicucci

analyst
#50

Hi, good morning, everyone. I also wanted to touch on the backlog remarks. Clearly, Paragon was somewhat dilutive to the adjusted EBITDA margin this quarter. As we consider these fresh orders coming in, how should we view the margin profile in backlog right now? I mean, you did address it, I think, regarding the 2028 target, but I just want to set a baseline there.

Brian Schopfer

executive
#51

Yes, thanks, Nick. Look, I'd describe the margins in backlog as precisely what we anticipated and, you know, they give us the capacity to reach the figures, you know, we're discussing. You know, we truly and really consider our margin backlog more in terms of contribution margin rather than, you know, what the base margin is. You know, I don't believe there's anything too frightening in there that concerns us from a margin standpoint moving forward. You know, the sole perhaps remark I'd offer is, you know, certain project business may be somewhat lower margin. I think the teams have performed very well, working diligently to ensure that the incremental margin on those larger projects genuinely benefits Mirion over the long term. We're concentrated on margins, and we're concentrated on cash when it comes to these bigger business projects.

Tom Logan

executive
#52

Good morning, everyone — thanks for spending part of your day with us, and thank you for the backing you've shown. Once again, this was a significant quarter for our company. The momentum we're seeing in orders has us feeling very good. Our confidence in this year's outlook remains intact. Our confidence also remains intact when it comes to pushing toward that 30-point EBITDA goal. As I've pointed out before over the years, we assembled this business while facing extremely tough headwinds, and we always discovered a path to expand the top line and create value at a pace that beat the markets and the peer set at large. To now have tailwinds — not just any tailwinds, but generational ones — lifting the entire business is incredibly thrilling; we can't wait to keep demonstrating what we're capable of, and we look forward to talking with each of you on our Q2 call. Many thanks.

Operator

operator
#53

That brings today's call to a close. At this point, feel free to drop off the lines. We appreciate you joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.